Skip to Content

Join the 'Xeljanz XR' group to help and get support from people like you.

Xeljanz XR News

Arthritis Drug Shows Promise for Ulcerative Colitis

Posted 4 May 2017 by Drugs.com

WEDNESDAY, May 3, 2017 – A new study finds that people with moderate to severe ulcerative colitis who haven't done well on other treatments may find relief with Xeljanz (tofacitinib), a drug currently used to treat arthritis. Ulcerative colitis is a chronic inflammatory bowel disease. It affects about 700,000 Americans, according to the Crohn's and Colitis Foundation (CCF). The illness causes inflammation, irritation, swelling and sores on the lining of the large intestine. Symptoms include diarrhea with blood or pus and abdominal discomfort, according to CCF. "There is still a substantial unmet need for new treatments for patients with ulcerative colitis," said study lead author Dr. William Sandborn. He is professor of medicine and chief of the division of gastroenterology at the University of California, San Diego. Xeljanz targets certain proteins involved in the body's inflammatory ... Read more

Related support groups: Ulcerative Colitis, Ulcerative Colitis - Active, Ulcerative Colitis - Maintenance, Xeljanz, Xeljanz XR, Tofacitinib

Early Treatment Equals Better Results for Rheumatoid Arthritis

Posted 25 Apr 2017 by Drugs.com

TUESDAY, April 25, 2017 – Treating rheumatoid arthritis early may make for better outcomes, a new study suggests. Patients who were treated within six months of developing the first signs of the autoimmune disease did better in the long run and were less likely to suffer early death, British researchers found. The findings stem from an analysis of more than 600 patients who were initially diagnosed with rheumatoid arthritis (RA) between 1990 and 1994. They were tracked for over 20 years. Over the study time frame, investigators assessed key symptoms of RA, such as swollen and/or tender joints, and indications of disability. All deaths were also noted. The research team found that patients who started treatment for RA within the first half-year after the first symptoms surfaced tended to have no greater levels of disability over a 20-year period than patients who required no treatment. ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Otezla, Imuran, Sulfasalazine, Orencia, Rituximab, Arava, Leflunomide, Azathioprine, Juvenile Rheumatoid Arthritis, Xeljanz, Juvenile Idiopathic Arthritis, Infliximab

Could a Germ Link Gum Disease, Rheumatoid Arthritis?

Posted 15 Dec 2016 by Drugs.com

THURSDAY, Dec. 15, 2016 – A specific germ may help explain the long-noticed connection between gum disease and rheumatoid arthritis, a new study suggests. The discovery might also point to the potential origins of the painful joint illness. "If we're right, this will totally change the view of rheumatoid arthritis and treatment of patients," said study co-author Dr. Felipe Andrade. But, Andrade, an associate professor of medicine at the Johns Hopkins University School of Medicine in Baltimore, cautioned that this is "an early finding that needs confirmation by others." Rheumatoid arthritis is a chronic form of arthritis linked to an overactive immune system. It can affect a variety of body systems, not just the joints. The disease affects roughly 1.5 million U.S. adults, according to the U.S. Centers for Disease Control and Prevention. For more than a century, scientists have noticed ... Read more

Related support groups: Rheumatoid Arthritis, Methotrexate, Humira, Oral and Dental Conditions, Enbrel, Remicade, Plaquenil, Hydroxychloroquine, Rituxan, Otezla, Gingivitis, Imuran, Sulfasalazine, Orencia, Rituximab, Arava, Leflunomide, Azathioprine, Juvenile Rheumatoid Arthritis, Xeljanz

Arthritis Drug May Help With Type of Hair Loss

Posted 22 Sep 2016 by Drugs.com

THURSDAY, Sept. 22, 2016 – For people who suffer from a condition that causes disfiguring hair loss, a drug used for rheumatoid arthritis might regrow their hair, a new, small study suggests. Alopecia areata is an autoimmune disease that causes patchy or complete hair loss, including on the head, body, eyebrows and eyelashes. Researchers found that more than 50 percent of 66 patients treated with the drug Xeljanz (tofacitinib citrate) saw hair regrowth in three months. "There is hope now that we will have more to tell patients than get counseling and a wig," said lead researcher Dr. Brett King, an assistant professor of dermatology at the Yale School of Medicine, in New Haven, Conn. Xeljanz appears to work by stopping the immune system's attack on hair follicles, King said. In addition, the researchers have identified genes that might predict a patient's response to treatment, he said. ... Read more

Related support groups: Rheumatoid Arthritis, Alopecia, Xeljanz, Xeljanz XR

Ask a Question

Further Information

Related Condition Support Groups

Rheumatoid Arthritis

Xeljanz XR Patient Information at Drugs.com